Saruparib (AZD-5305): A Comprehensive Clinical and Scientific Review of a First-in-Class PARP1-Selective Inhibitor

Executive Summary

Saruparib (AZD-5305) is a first-in-class, orally bioavailable, investigational targeted therapy representing a significant evolution in the class of poly(ADP-ribose) polymerase (PARP) inhibitors. Developed by AstraZeneca, it is a highly potent and selective inhibitor and trapper of PARP1, an enzyme critical to the repair of single-strand DNA breaks. The foundational scientific hypothesis for Saruparib's development was to uncouple the established antitumor efficacy of PARP inhibition from the dose-limiting hematologic toxicities associated with first-generation, dual PARP1/2 inhibitors. Preclinical and clinical evidence suggests that while PARP1 inhibition is sufficient for inducing synthetic lethality in cancers with homologous recombination repair (HRR) deficiencies, the co-inhibition of PARP2 is a primary driver of myelosuppression.

Preclinical studies in patient-derived xenograft models demonstrated that Saruparib possesses superior antitumor activity compared to the first-generation PARP inhibitor olaparib, achieving higher rates of complete response and a significantly longer duration of progression-free survival. These studies also validated the safety hypothesis, showing minimal hematologic toxicity at clinically relevant exposures.

The foundational clinical evidence for Saruparib comes from the Phase I/IIa PETRA trial (NCT04644068), which evaluated the agent in heavily pretreated patients with advanced solid tumors harboring mutations in HRR genes such as BRCA1/2, PALB2, or RAD51C/D. The trial demonstrated that Saruparib has a favorable safety and tolerability profile, with substantially lower rates of grade ≥3 hematologic adverse events compared to historical data for dual PARP1/2 inhibitors. This improved safety profile allowed for significantly higher drug exposures and target coverage, leading to robust and durable target engagement (≥90% PARylation inhibition). Promising clinical activity was observed across multiple tumor types and dose levels, leading to the selection of 60 mg once daily as the recommended Phase 2 dose (RP2D). This dose was chosen based on an optimal balance of efficacy and safety, prioritizing a superior therapeutic index over the maximum tolerated dose.

Building on these results, Saruparib is being advanced through a comprehensive late-stage clinical program. Key ongoing pivotal trials include EvoPAR-Prostate01 (NCT06120491), a Phase III study evaluating Saruparib in combination with novel hormonal agents for metastatic castration-sensitive prostate cancer, and EvoPAR-Breast01 (NCT06380751), a Phase III study assessing Saruparib plus the next-generation selective estrogen receptor degrader (SERD) camizestrant in first-line HR-positive, HER2-negative advanced breast cancer. These trials are strategically designed to establish Saruparib not only as a potential best-in-class agent but also as a new standard of care in major oncology indications. Its improved therapeutic window positions it as a highly attractive backbone for future combination therapies, with the potential to expand the benefit of PARP inhibition to a broader patient population.

Introduction: The Rationale for a New Generation of PARP Inhibitors

The Established Role of First-Generation PARP Inhibitors

The introduction of poly(ADP-ribose) polymerase (PARP) inhibitors marked a paradigm shift in the treatment of cancers characterized by defects in the homologous recombination repair (HRR) pathway. First-generation agents, including olaparib, rucaparib, niraparib, and talazoparib, function as dual inhibitors of both PARP1 and PARP2 enzymes.[1] These drugs exploit the concept of synthetic lethality: in cancer cells with pre-existing HRR deficiency (HRD), such as those with germline or somatic mutations in

BRCA1 or BRCA2 genes, the pharmacological inhibition of PARP-mediated single-strand break repair leads to the accumulation of cytotoxic double-strand breaks during DNA replication, ultimately causing selective tumor cell death.[1] This targeted approach has led to significant improvements in progression-free and overall survival, establishing PARP inhibitors as a standard of care in multiple settings for ovarian, breast, prostate, and pancreatic cancers.[1]

The Clinical Challenge: Dose-Limiting Toxicities

Despite their transformative impact, the clinical utility of first-generation PARP inhibitors is often constrained by a consistent pattern of dose-limiting toxicities.[1] The most prominent of these are hematologic adverse events, including anemia, neutropenia, and thrombocytopenia, which are considered a class-wide effect.[3] These cytopenias, along with significant gastrointestinal side effects such as nausea and fatigue, frequently necessitate dose interruptions, reductions, or even discontinuation of therapy.[5] Such modifications can compromise the maintenance of optimal therapeutic drug exposure, potentially limiting the full efficacy and durability of the treatment. The overlapping myelosuppressive effects also present a substantial challenge for developing combination regimens, particularly with cytotoxic chemotherapy or other agents that impact bone marrow function.[1]

The Scientific Hypothesis for PARP1 Selectivity

The persistent challenge of toxicity prompted a deeper investigation into the distinct biological roles of the PARP1 and PARP2 isoforms. A growing body of evidence began to suggest that the therapeutic and toxic effects of dual inhibitors could be uncoupled. PARP1 is the primary sensor of DNA damage, accounting for 80-95% of cellular PARylation activity, and its inhibition and trapping on DNA are considered sufficient to induce synthetic lethality in HRD tumors.[1] Conversely, preclinical animal models have implicated PARP2 in the survival and maintenance of hematopoietic stem and progenitor cells.[1]

This understanding gave rise to a clear and compelling scientific hypothesis: the inhibition of PARP2 by first-generation agents may be a primary, on-target driver of the observed clinical hematologic toxicity, while offering minimal contribution to the desired antitumor effect.[1] Consequently, the rational design of a potent and highly selective PARP1 inhibitor could theoretically retain or even enhance anticancer activity while significantly mitigating the myelosuppression associated with PARP2 inhibition.[1] Such an agent would possess a wider therapeutic window, enabling more consistent dosing at optimal levels and creating a more favorable backbone for combination therapies. The development of Saruparib (AZD-5305) by AstraZeneca was a direct and deliberate effort to validate this hypothesis in the clinic, aiming to create a next-generation, best-in-class PARP inhibitor by "dialing out" the off-tumor effects of PARP2.[5] This strategic shift from broad PARP inhibition to isoform-specific targeting represents a maturation of the field, where optimizing the therapeutic index is recognized as being as critical as demonstrating initial efficacy.

Molecular Profile and Differentiated Mechanism of Action

Chemical Identity

Saruparib is a small molecule inhibitor identified by the development code AZD-5305. Its systematic chemical name is 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide.[13] The compound has a molecular formula of

C22​H26​N6​O2​ and a molecular weight of 406.48 g/mol.[14]

Mechanism of Action: PARP1 Inhibition and DNA Trapping

The anticancer activity of Saruparib is derived from a dual mechanism that specifically targets PARP1. PARP1 is a nuclear enzyme that plays a central role in the DNA damage response (DDR) by recognizing and binding to sites of single-strand DNA breaks (SSBs).[3] Upon binding, it catalyzes the synthesis of long chains of poly(ADP-ribose) (PAR), a process known as PARylation, which recruits other DNA repair proteins to the site of damage.[1]

Saruparib exerts its effect through two distinct but complementary actions:

1. Catalytic Inhibition: Saruparib binds to the catalytic domain of PARP1, preventing the PARylation process. This action alone disrupts the efficient repair of SSBs.[1]
2. PARP Trapping: Perhaps more critically for its cytotoxicity, Saruparib stabilizes the PARP1 enzyme while it is bound to DNA, forming a highly stable ternary complex (inhibitor-PARP1-DNA).[1] This "trapped" complex acts as a physical obstruction to the DNA replication machinery. When a replication fork encounters this roadblock, it collapses, leading to the formation of a highly toxic DNA double-strand break (DSB).[1]

In normal, healthy cells, these DSBs can be efficiently repaired by the high-fidelity HRR pathway. However, in cancer cells with HRD (e.g., BRCA1/2 mutations), this pathway is compromised. The accumulation of unrepaired DSBs leads to profound genomic instability and, ultimately, programmed cell death, or apoptosis.[1] This selective killing of HRD cancer cells while sparing normal cells is the principle of synthetic lethality.

Unprecedented Selectivity

The defining feature of Saruparib is its exceptional selectivity for PARP1 over other members of the PARP family, most notably PARP2. In both biochemical and cellular assays, Saruparib has demonstrated over 500-fold greater selectivity for inhibiting PARP1 compared to PARP2.[1] This high degree of specificity has been functionally confirmed in cellular experiments using isogenic cell lines. In wild-type cells or cells lacking PARP2, Saruparib potently inhibits PARylation. However, in cells where PARP1 has been knocked out (leaving PARP2 as the primary PARP enzyme), a dramatic shift in potency is observed, requiring over 500 times the concentration of Saruparib to achieve similar PARylation inhibition.[17] In contrast, first-generation PARP inhibitors show overlapping activity curves across all three cell lines (wild-type, PARP1-KO, and PARP2-KO), confirming their dual-targeting nature.[17]

Furthermore, Saruparib is a potent and selective trapper of PARP1. In cellular assays, it induces dose-dependent trapping of PARP1 on chromatin at low nanomolar concentrations. Critically, no trapping of PARP2 is detected even at micromolar concentrations of Saruparib.[17] This stands in stark contrast to agents like olaparib, niraparib, and talazoparib, which induce trapping of both PARP1 and PARP2 at similar concentrations.[17] This highly specific mechanism of action is the foundation of Saruparib's differentiated clinical profile.

Table 1: Chemical and Pharmacological Properties of Saruparib (AZD-5305)

Property	Description	Source(s)
Generic Name	Saruparib	3
Development Code	AZD-5305	11
Chemical Name	5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide	13
Molecular Formula	C22​H26​N6​O2​	14
Molecular Weight	406.48 g/mol	14
Drug Class	PARP1-selective inhibitor and trapper	4
Primary Molecular Target	Poly (ADP-Ribose) Polymerase-1 (PARP1)	6
Selectivity Profile	>500-fold for PARP1 vs. PARP2	1
Route of Administration	Oral	4

The Preclinical Case for PARP1 Selectivity

Before advancing into human trials, Saruparib was subjected to a rigorous preclinical evaluation that not only confirmed its hypothesized safety benefits but also revealed potentially superior efficacy compared to first-generation PARP inhibitors.

Superior In Vivo Antitumor Efficacy

In a series of studies using patient-derived xenograft (PDX) models of breast, ovarian, and pancreatic cancer harboring BRCA1, BRCA2, or PALB2 mutations, Saruparib demonstrated robust and durable antitumor activity.[1] When compared directly with the established first-generation inhibitor olaparib, Saruparib showed clear superiority. Animal models treated with Saruparib at doses as low as 0.1 mg/kg once daily achieved a greater depth of tumor regression and a significantly longer duration of response than those treated with a standard preclinical dose of olaparib (100 mg/kg).[1]

Quantitative analysis from these head-to-head comparisons was striking. Saruparib achieved a preclinical complete response rate of 75%, more than double the 37% rate observed with olaparib.[8] This translated into a profound difference in long-term tumor control; the median preclinical progression-free survival in the Saruparib-treated group was over 386 days, compared to just 90 days for the olaparib-treated group.[8] This enhanced efficacy was not just an incremental improvement but a fundamental shift in the degree of tumor control achievable. The durability of these responses was a key finding, with tumor regressions often persisting long after treatment was withdrawn, suggesting that Saruparib induces a deeper and more lasting level of genomic catastrophe in cancer cells, potentially delaying the emergence of resistance.[1] Furthermore, Saruparib was shown to be effective in models where first-generation agents had little to no effect and demonstrated a superior ability to impair the development of visceral metastases, ultimately extending the lifespan of mice in ovarian cancer PDX models.[11]

Validation of Reduced Hematologic Toxicity

The primary hypothesis driving Saruparib's development—that PARP1 selectivity would mitigate myelosuppression—was directly validated in preclinical toxicology models. In rat models, Saruparib monotherapy caused minimal hematologic toxicity at exposures predicted to be clinically efficacious.[1] This finding was a crucial differentiator from first-generation PARP inhibitors, which are known to cause sustained reductions in red blood cell precursors in animal models.[1] This preclinical safety data provided a strong "go" signal for clinical development, suggesting that the improved therapeutic window sought by its designers was achievable.

Synergy in Combination

Preclinical studies also established a strong rationale for evaluating Saruparib in combination regimens. In ovarian cancer PDX models, Saruparib potentiated the efficacy of the platinum-based chemotherapy agent carboplatin (CPT).[11] The combination was highly effective, even in tumors that did not respond well to platinum therapy alone, and stabilized tumor growth at suboptimal doses where Saruparib monotherapy was ineffective.[11] Additionally, strong synergistic activity was observed when Saruparib was combined with the ATR inhibitor ceralasertib. This combination was effective in overcoming acquired resistance to PARP inhibitors, achieving complete tumor regressions in PARPi-resistant breast and ovarian cancer models.[8] These data highlighted Saruparib's potential not only as a powerful monotherapy but also as a versatile and potent combination partner.

The Clinical Development Program: An Overview

The clinical development strategy for Saruparib has been comprehensive and strategically designed, progressing from a foundational first-in-human study to a broad program of combination therapy evaluations and large-scale, registration-intent Phase III trials. The program aims to establish Saruparib's superiority over existing agents and position it as a new standard of care in key cancer indications.

The cornerstone of the program is the PETRA (NCT04644068) trial, a modular Phase I/IIa study that provided the initial human data on safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of Saruparib as a monotherapy, while also serving as a platform to explore various combination regimens.[18] Building on the monotherapy data, the

PETRANHA (NCT05367440) trial was initiated to specifically evaluate the safety and feasibility of combining Saruparib with novel hormonal agents (NHAs) in metastatic prostate cancer, a setting where such combinations have already shown promise with first-generation agents.[7]

Success in these early-phase trials has paved the way for an ambitious Phase III program designed to secure regulatory approval and redefine treatment paradigms. The EvoPAR-Prostate01 (NCT06120491) trial is a large, placebo-controlled study aiming to establish the benefit of adding Saruparib to standard NHA therapy in men with metastatic castration-sensitive prostate cancer (mCSPC), including cohorts with and without HRR mutations.[25] In parallel, the

EvoPAR-Breast01 (NCT06380751) trial is a head-to-head study comparing a novel combination of Saruparib plus the next-generation SERD camizestrant against the current first-line standard of care (a CDK4/6 inhibitor plus endocrine therapy) in patients with HR-positive, HER2-negative advanced breast cancer with specific HRR mutations.[27] This comprehensive clinical pathway reflects a high degree of confidence in Saruparib's differentiated profile.

Table 2: Summary of Key Clinical Trials for Saruparib (AZD-5305)

Trial Name / Identifier	Phase	Patient Population	Intervention(s)	Primary Objective(s)	Status
PETRA / NCT04644068	Phase I/IIa	Advanced solid tumors w/ HRRm (BRCA1/2, PALB2, RAD51C/D)	Saruparib monotherapy & combinations (chemo, ADCs, etc.)	Safety, tolerability, Recommended Phase 2 Dose (RP2D)	Closed to recruitment 4
PETRANHA / NCT05367440	Phase I/IIa	Metastatic prostate cancer (mCRPC & mCSPC)	Saruparib + Novel Hormonal Agents (NHAs)	Safety, tolerability, drug-drug interactions (DDIs)	Ongoing 7
EvoPAR-Prostate01 / NCT06120491	Phase III	Metastatic castration-sensitive prostate cancer (mCSPC) w/ and w/o HRRm	Saruparib + NHA vs. Placebo + NHA	Radiographic Progression-Free Survival (rPFS)	Recruiting 25
EvoPAR-Breast01 / NCT06380751	Phase III	1L HR+/HER2- advanced breast cancer w/ BRCA1/2 or PALB2 mutations	Saruparib + Camizestrant vs. Standard of Care (CDK4/6i + ET)	Progression-Free Survival (PFS)	Recruiting 27

In-Depth Analysis of the PETRA Trial: Foundational Monotherapy Data (NCT04644068)

The PETRA trial is the first-in-class, first-in-human study of Saruparib and has provided the foundational clinical data supporting its continued development. Its results have been pivotal in validating the PARP1-selectivity hypothesis in patients.

Study Design and Population

PETRA is a modular, open-label, multi-center Phase I/IIa study designed to assess the safety, tolerability, PK, PD, and preliminary efficacy of Saruparib, both as a monotherapy and in combination with other anticancer agents.[18] The monotherapy arm enrolled a heavily pretreated patient population with a median of 3.5 prior lines of therapy.[16] Eligible patients had advanced (metastatic or locally advanced) solid tumors, including breast, ovarian, prostate, or pancreatic cancer, with confirmed germline or somatic mutations in key HRR genes:

BRCA1, BRCA2, PALB2, RAD51C, or RAD51D.[5] The study included both a dose-escalation phase to determine the maximum tolerated dose (MTD) and a dose-expansion/optimization phase to identify the recommended Phase 2 dose (RP2D).[4]

Pharmacokinetics (PK) and Pharmacodynamics (PD)

The pharmacokinetic profile of Saruparib in patients proved to be a key differentiator. PK exposures were found to be dose-proportional across the tested range.[16] Critically, Saruparib achieved significantly higher drug exposures and sustained target coverage compared to all approved first-generation PARP inhibitors.[5] Data presented from the trial showed that the mean fold coverage over the target effective concentration for Saruparib ranged from 7.12 at the 10 mg dose to 55.88 at higher doses. This far exceeds the coverage achieved by olaparib (3.13), rucaparib (2.42), talazoparib (0.5), and niraparib (0.36).[6] This ability to achieve much higher, more consistent drug levels is a direct consequence of its improved tolerability.

This superior PK translated into robust and durable pharmacodynamic effects. Across all dose levels, Saruparib demonstrated maximal target engagement, as measured by the inhibition of PARylation in both peripheral blood mononuclear cells (PBMCs) and paired tumor biopsies. PARylation inhibition was consistently ≥90%, confirming that the drug was achieving a profound and sustained biological effect on its target in patients.[5]

Clinical Safety and Tolerability

The safety data from PETRA provided the first clinical validation of the PARP1-selectivity hypothesis. Saruparib was well-tolerated across all dose-escalation cohorts, from 10 mg to 140 mg daily, with no dose-limiting toxicities (DLTs) reported.[6] The overall safety profile was favorable and manageable. The most common treatment-emergent adverse events (TEAEs) of any grade were nausea (34.4%) and anemia (21.3%).[6]

Most importantly, the rates of clinically significant, grade ≥3 hematologic toxicities were notably low, especially when compared to historical data for dual PARP1/2 inhibitors. Across the initial dose-escalation cohort of 61 patients, the rate of grade ≥3 anemia was 14.8%, grade ≥3 neutropenia was 6.6%, and grade ≥3 thrombocytopenia was 3.3%.[33] This favorable safety profile resulted in very infrequent dose modifications. In the initial cohort, only two patients (3.3%) required a dose reduction, and there were no treatment discontinuations due to Saruparib-related adverse events at the time of data cutoff.[6] This high degree of tolerability allows patients to remain on their prescribed dose for longer, maximizing the potential for clinical benefit.

Clinical Efficacy and Dose Optimization

Promising signs of clinical activity were observed early in the trial, with objective responses seen at every dose level and across different tumor types (BRCA-mutant ovarian, breast, and prostate cancer) and mutation types (BRCA1/2, PALB2).[5] Importantly, responses were also documented in patients who had previously been treated with and progressed on a first-generation PARP inhibitor, suggesting a potential to overcome some forms of resistance.[33]

The dose-optimization phase of the trial was designed in accordance with the FDA's Project Optimus initiative, which encourages selecting a dose that maximizes the risk-benefit ratio for patients rather than simply advancing the MTD. This phase primarily focused on patients with HER2-negative breast cancer and compared three dose levels: 20 mg, 60 mg, and 90 mg once daily.[5]

The results of this comparison led to the selection of 60 mg once daily as the RP2D.[3] While 90 mg was identified as the MTD, the 60 mg dose demonstrated a clearly superior therapeutic index. The 60 mg cohort achieved a slightly higher objective response rate (ORR) of 48.4% compared to 46.7% in the 90 mg cohort, and a longer median duration of response (DOR) of 7.3 months versus 5.6 months.[5] Furthermore, the 60 mg dose was associated with a significantly better safety profile, most notably a more than three-fold lower rate of grade ≥3 anemia (11.3% at 60 mg vs. 39% at 90 mg).[35] The median progression-free survival (PFS) for the 60 mg cohort was a promising 9.1 months.[3] This data-driven decision to select the 60 mg dose prioritizes long-term tolerability and sustainability of treatment, which is crucial for maximizing durable benefit and is a critical attribute for a drug intended for broad use in combination regimens.

Table 3: Efficacy and Safety Outcomes from PETRA Dose-Optimization Cohorts (HER2-Negative Breast Cancer)

Endpoint	Saruparib 20 mg QD (n=28)	Saruparib 60 mg QD (n=31)	Saruparib 90 mg QD (n=30)
Objective Response Rate (ORR)	35.7%	48.4%	46.7%
Median Duration of Response (DOR)	6.1 months	7.3 months	5.6 months
Median Progression-Free Survival (PFS)	4.6 months	9.1 months	Data Immature
Grade ≥3 Anemia Rate	15.2%	11.3%	39.0%
Sources: 3

Saruparib in Combination Regimens: Expanding the Therapeutic Horizon

A central element of Saruparib's development strategy is its potential as a superior combination partner, enabled by its favorable safety profile. Early clinical investigations are already underway to explore its utility in various combination regimens, aiming to enhance efficacy and address different mechanisms of tumorigenesis and resistance.

The PETRANHA Study (NCT05367440): Combination with Novel Hormonal Agents (NHAs)

The PETRANHA study is a Phase I/IIa, multi-arm, open-label trial specifically designed to assess the safety, tolerability, and potential for drug-drug interactions (DDIs) when Saruparib is combined with standard-of-care novel hormonal agents (NHAs) in patients with metastatic prostate cancer.[7] This study is a direct response to the clinical success observed with combinations of first-generation PARP inhibitors and NHAs (e.g., olaparib plus abiraterone in the PROpel study), which have demonstrated improved outcomes in metastatic castration-resistant prostate cancer (mCRPC).[7]

The trial enrolls patients with either mCRPC or metastatic castration-sensitive prostate cancer (mCSPC) and assigns them to one of three arms, receiving Saruparib 60 mg once daily in combination with:

• Arm 1: Enzalutamide (160 mg OD)
• Arm 2: Abiraterone acetate (1000 mg OD) plus prednisone
• Arm 3: Darolutamide (600 mg BID) [7]

Interim safety results from an analysis of 48 patients were presented with a data cutoff of July 10, 2023.[24] The median duration of Saruparib exposure was 6.3 months. The combinations were found to be safe and tolerable, with no new safety signals emerging. The most common adverse events (AEs) were consistent with the known profiles of the individual agents: anemia (52.1% any grade; 16.7% grade ≥3), fatigue (50.0% any grade; 2.1% grade ≥3), and neutropenia (33.3% any grade; 6.3% grade ≥3).[24] Importantly, AEs leading to discontinuation were uncommon, and pharmacokinetic analysis revealed no clinically significant DDIs between Saruparib and any of the three NHAs.[24] These findings provide a strong safety foundation for the ongoing pivotal Phase III EvoPAR-Prostate01 trial.

PETRA Modular Combinations (NCT04644068)

The modular design of the PETRA trial serves as an efficient platform to investigate Saruparib's potential with a diverse range of anticancer agents beyond monotherapy. The study protocol includes distinct modules to formally evaluate Saruparib in combination with:

• Standard Chemotherapies: Paclitaxel, with or without carboplatin.[4]
• Antibody-Drug Conjugates (ADCs): Trastuzumab deruxtecan (T-DXd) and datopotamab deruxtecan (Dato-DXd).[4]
• Novel Endocrine Therapy: The next-generation SERD camizestrant.[4]

This forward-looking strategy is mechanistically driven. Combining Saruparib with ADCs that carry a topoisomerase I inhibitor payload (e.g., deruxtecan) is particularly compelling. These ADCs induce single- and double-strand DNA breaks, and the concurrent inhibition of PARP1 by Saruparib is expected to prevent the repair of this damage, leading to a powerful synergistic antitumor effect.[38] Preclinical data has also shown that combining Saruparib with AZD8205, an ADC targeting B7-H4, results in higher antitumor activity than either monotherapy.[38] The improved therapeutic index of Saruparib is the key enabler for these combinations, providing the necessary safety "headroom" to manage potential overlapping toxicities with potent agents like chemotherapy and ADCs.

Pivotal Phase III Trials: The Path to Registration

Following the successful outcomes of the PETRA trial, Saruparib has progressed into a robust and ambitious Phase III clinical program. These large, randomized, registration-intent trials are designed to definitively establish its efficacy and safety in major cancer indications and are positioned not merely to gain approval in later-line settings but to challenge and redefine the first-line standard of care.

EvoPAR-Prostate01 (NCT06120491)

The EvoPAR-Prostate01 trial is a global, randomized, double-blind, placebo-controlled Phase III study evaluating Saruparib in men with metastatic castration-sensitive prostate cancer (mCSPC).[25] This trial aims to move PARP inhibition into an earlier, hormone-sensitive disease setting where the potential for durable benefit may be greatest.

The study is designed to enroll approximately 1,800 participants who will be prospectively assigned to one of two cohorts based on their HRR gene mutation status (HRRm or non-HRRm).[25] Within each cohort, patients will be randomized in a 1:1 ratio to receive either:

• Experimental Arm: Saruparib plus a physician's choice of NHA (abiraterone, darolutamide, or enzalutamide).
• Control Arm: Placebo plus a physician's choice of NHA.[25]

The primary endpoint of the trial is radiographic progression-free survival (rPFS), with overall survival (OS) as a key secondary endpoint.[25] The inclusion of a large non-HRRm cohort is a significant strategic element. While the greatest benefit is anticipated in the HRRm population, data from first-generation PARPi trials have suggested a potential benefit in a broader population, possibly due to interactions with the androgen receptor pathway.[40] A positive outcome in the non-HRRm cohort could substantially expand the indicated patient population for Saruparib.

EvoPAR-Breast01 (NCT06380751)

The EvoPAR-Breast01 trial is a randomized, open-label, Phase III study that represents a particularly bold strategic move. It is designed to evaluate Saruparib in the first-line treatment of patients with hormone receptor-positive (HR+), HER2-negative advanced breast cancer harboring a documented germline or somatic loss-of-function mutation in BRCA1, BRCA2, or PALB2.[27]

This trial directly challenges the current, entrenched standard of care for this patient population. Approximately 500 participants will be randomized in a 2:2:1 ratio to one of three arms:

• Arm 1 (Experimental): Saruparib plus camizestrant (a next-generation oral SERD).
• Arm 2 (Standard of Care): Physician's choice of a CDK4/6 inhibitor (abemaciclib, ribociclib, or palbociclib) plus a physician's choice of endocrine therapy (ET).
• Arm 3 (Exploratory): Physician's choice of a CDK4/6 inhibitor plus camizestrant.[27]

The primary endpoint is progression-free survival (PFS), based on a comparison between the experimental Arm 1 and the standard-of-care Arm 2.[43] This high-risk, high-reward trial design, pitting a novel combination of two next-generation AstraZeneca assets against the dominant CDK4/6 inhibitor class, underscores the company's confidence in Saruparib's profile. A successful outcome would be practice-changing and could establish a new first-line standard for this genetically defined patient population.

Comparative Assessment and Competitive Landscape

The totality of the available data allows for a direct comparison of Saruparib's profile against the approved first-generation, dual PARP1/2 inhibitors. This assessment highlights several key areas of differentiation that form the basis of Saruparib's potential best-in-class status. The primary distinction lies in its mechanism, which drives downstream advantages in pharmacokinetics, safety, and potentially efficacy. By selectively targeting PARP1 and avoiding PARP2, Saruparib was designed to optimize the therapeutic index—a goal that appears to be validated by early clinical data.

The superior safety profile, particularly the lower incidence of severe hematologic toxicities, is the most profound clinical differentiator observed to date. This improved tolerability enables more consistent dosing with fewer interruptions or reductions, which in turn allows for the maintenance of significantly higher and more sustained drug exposures above the target effective concentration. This robust pharmacokinetic and pharmacodynamic profile, combined with compelling preclinical head-to-head efficacy data versus olaparib, provides a strong rationale for its potential to deliver superior long-term clinical outcomes for patients.

Table 4: Head-to-Head Profile Comparison: Saruparib vs. First-Generation PARP Inhibitors

Parameter	Saruparib (AZD-5305)	First-Generation PARPi (Representative Data)
PARP1/PARP2 Selectivity	Highly selective (>500-fold for PARP1)	Dual / Non-selective inhibitors of PARP1 and PARP2
Target PK Coverage	Significantly higher; >30-fold coverage over target effective concentration	Lower; e.g., Olaparib (~3-fold), Niraparib (~0.4-fold)
PD Target Engagement	Robust and durable; ≥90% PARylation inhibition achieved in patients	Variable; efficacy may be limited by toxicity-driven dose reductions
Rate of Grade ≥3 Anemia	Favorable; ~11-15% in monotherapy trials	Historically higher rates reported in pivotal trials
Rate of Grade ≥3 Neutropenia	Favorable; ~7-11% in monotherapy trials	Historically higher rates reported in pivotal trials
Rate of Dose Reductions	Infrequent; ~14% at the 60 mg RP2D	More frequent, a common clinical management strategy
Rate of Discontinuations (due to AEs)	Very low; ~3.5% at the 60 mg RP2D	Higher rates reported in pivotal trials
Preclinical Efficacy vs. Olaparib	Superior; Higher complete response rate (75% vs 37%) and longer PFS (>386 vs 90 days)	Benchmark for preclinical efficacy
Sources: 1

Regulatory Status

Saruparib (AZD-5305) is currently an investigational drug and has not received marketing authorization from any regulatory agency worldwide. It is not approved by the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for any clinical indication.[44] Its status is that of a compound in late-stage clinical development, with its future regulatory submissions contingent upon the outcomes of the ongoing pivotal Phase III trials, primarily EvoPAR-Prostate01 and EvoPAR-Breast01.

A review of publicly available information indicates that, to date, Saruparib has not been granted any special regulatory designations, such as FDA Breakthrough Therapy Designation or EMA PRIME (PRIority MEdicines) status.[48] Such designations are typically sought after compelling preliminary clinical evidence from early- or mid-stage trials suggests a substantial improvement over available therapies. The timing of any such application would likely follow the initial readouts from its pivotal study program.

Expert Synthesis and Future Outlook

Potential as a "Best-in-Class" Agent

Saruparib (AZD-5305) represents a triumph of rational drug design, successfully translating a clear scientific hypothesis into a clinical asset with a highly differentiated profile. The totality of evidence from preclinical and early clinical studies strongly supports its potential to become a best-in-class PARP inhibitor.[3] The foundational premise—that selective PARP1 inhibition can uncouple antitumor efficacy from PARP2-mediated hematologic toxicity—has been validated in the PETRA trial. The resulting favorable safety profile is not merely an incremental improvement but a transformative feature that enables a cascade of downstream benefits: superior pharmacokinetics with higher target coverage, robust pharmacodynamics, and infrequent need for dose modifications. This combination of attributes provides a compelling rationale to expect durable and potentially superior efficacy in the ongoing pivotal trials compared to first-generation agents.[20]

The Cornerstone of Future Combinations

The most significant strategic advantage conferred by Saruparib's improved therapeutic index is its potential to become the preferred PARP inhibitor backbone for a new generation of combination therapies.[3] The dose-limiting myelosuppression of dual PARP1/2 inhibitors has historically constrained their use with cytotoxic chemotherapy, certain antibody-drug conjugates, and other DNA damage response inhibitors due to overlapping toxicities. Saruparib's cleaner hematologic profile creates the necessary safety "headroom" to explore these mechanistically synergistic combinations more aggressively and safely.[3] Its development opens the door to novel regimens that could overcome resistance, deepen responses, and expand the utility of PARP inhibition into new tumor types and broader patient populations, including those without canonical HRR mutations.[55]

Addressing Unmet Needs and Potential Challenges

The future outlook for Saruparib is exceptionally promising, yet challenges remain. While preclinical data suggest that Saruparib may delay the onset of resistance, acquired resistance will inevitably emerge as a clinical challenge. Mechanisms such as the restoration of HRR function through secondary BRCA reversion mutations, which have been observed in the context of first-generation PARPi, are also likely to affect Saruparib.[8] Ongoing research is appropriately focused on this area, with preclinical studies already showing that combinations with agents like carboplatin or the ATR inhibitor ceralasertib can elicit profound responses in models with acquired resistance to PARP inhibitors.[8] Another critical area for future development is the refinement of biomarkers. While patients with

BRCA1/2 mutations are the primary beneficiaries, expanding the use of Saruparib will depend on the development and validation of reliable assays to detect a broader state of "HRD-ness" in tumors, thereby identifying all patients who are likely to respond.[55]

Final Verdict

Saruparib (AZD-5305) stands as a landmark achievement in the evolution of targeted cancer therapy. It is the clinical embodiment of a successful strategy to refine a drug class by isolating a desired therapeutic mechanism from its associated toxicities. The robust preclinical data, combined with the compelling safety, pharmacokinetic, and preliminary efficacy results from the PETRA trial, have established a strong foundation for its late-stage development. The ambitious design of its pivotal Phase III program in prostate and breast cancer signals a clear intent to challenge and elevate the current standard of care. If the promising results from early studies are borne out in these larger trials, Saruparib is poised to become the new benchmark for PARP inhibition, offering a more effective, more tolerable, and more versatile therapeutic option for patients with HRR-deficient and other susceptible cancers.[8]

Works cited

1. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper | Clinical Cancer Research - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/clincancerres/article/28/21/4724/709832/Preclinical-Characterization-of-AZD5305-A-Next
2. Mechanisms of resistance to AZD5305 and olaparib in PDXs. A... - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/figure/Mechanisms-of-resistance-to-AZD5305-and-olaparib-in-PDXs-A-Quantification-by-IF-of-the_fig3_383427699
3. PARP1-Selective Inhibitors Generate Excitement in Solid Tumors - OncLive, accessed September 11, 2025, https://www.onclive.com/view/parp1-selective-inhibitors-generate-excitement-in-solid-tumors
4. A trial of AZD5305 for certain types of solid cancers that are getting worse (PETRA), accessed September 11, 2025, https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-of-azd5305-for-certain-types-of-solid-cancers-that-are-getting-worse-petra
5. First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors - OncLive, accessed September 11, 2025, https://www.onclive.com/view/first-in-class-parp1-selective-inhibitor-saruparib-shines-in-phase-1-trial-of-advanced-solid-tumors
6. Next-Generation PARP Inhibitor AZD5305 Shows Promising Safety Profile and Clinical Activity in Several Cancer Types - Targeted Oncology, accessed September 11, 2025, https://www.targetedonc.com/view/next-generation-parp-inhibitor-azd5305-shows-promising-safety-profile-and-clinical-activity-in-several-cancer-types
7. Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC). | Journal of Clinical Oncology - ASCO Publications, accessed September 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2023.41.6_suppl.TPS296
8. (PDF) The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/publication/383427699_The_PARP1_selective_inhibitor_saruparib_AZD5305_elicits_potent_and_durable_antitumor_activity_in_patient-derived_BRCA12-associated_cancer_models
9. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper - PubMed, accessed September 11, 2025, https://pubmed.ncbi.nlm.nih.gov/35929986/
10. Phase 1/2a study of AZD5305, a novel poly(adenosine diphosphate ribose) polymerase (PARP) 1-selective inhibitor in combination with new hormonal agents (NHAs) in patients (pts) with metastatic prostate cancer (mPC). - ASCO, accessed September 11, 2025, https://www.asco.org/abstracts-presentations/ABSTRACT394510
11. The PARP1 Inhibitor AZD5305 Impairs Ovarian Adenocarcinoma Progression and Visceral Metastases in Patient-derived Xenografts Alone and in Combination with Carboplatin, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10042207/
12. AstraZeneca accelerates early oncology pipeline across key strategic scientific platforms at AACR, accessed September 11, 2025, https://www.astrazeneca.com/media-centre/press-releases/2021/astrazeneca-accelerates-early-oncology-pipeline-across-key-strategic-scientific-platforms-at-aacr.html
13. Discovery of 5-{4-[(7-Ethyl-6-oxo-5,6-dihydro-1,5-naphthyridin-3-yl)methyl]piperazin-1-yl}-N-methylpyridine-2-carboxamide (AZD5305): A PARP1–DNA Trapper with High Selectivity for PARP1 over PARP2 and Other PARPs - ACS Publications - American Chemical Society, accessed September 11, 2025, https://pubs.acs.org/doi/abs/10.1021/acs.jmedchem.1c01012
14. AZD5305 | PARP - TargetMol, accessed September 11, 2025, https://www.targetmol.com/compound/azd5305
15. Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305 - Frontiers, accessed September 11, 2025, https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2022.979873/full
16. Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations | Cancer Research - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/cancerres/article/82/12_Supplement/CT007/701955/Abstract-CT007-PETRA-First-in-class-first-in-human
17. Preclinical Characterization of AZD5305, A Next-Generation, Highly Selective PARP1 Inhibitor and Trapper - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9623235/
18. Study of AZD5305 as monotherapy and in combination with anti ..., accessed September 11, 2025, https://www.astrazenecaclinicaltrials.com/study/D9720C00001/
19. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11348616/
20. Expert Opinion on Current Treatment Alternatives for Patients With Prostate Cancer Progressing From the Metastatic Hormone-Sensitive Stage to the Castration-Resistant Stage After Receiving Early Treatment Intensification - ResearchGate, accessed September 11, 2025, https://www.researchgate.net/publication/390186711_Expert_opinion_on_current_treatment_alternatives_for_patients_with_prostate_cancer_progressing_from_the_metastatic_hormone-sensitive_stage_to_the_castration-resistant_stage_after_receiving_early_treat
21. The PARP1 selective inhibitor saruparib (AZD5305) elicits potent and durable antitumor activity in patient-derived BRCA1/2-associated cancer models - PubMed, accessed September 11, 2025, https://pubmed.ncbi.nlm.nih.gov/39187844/
22. Abstract B058: Combination of the PARP1-selective inhibitor AZD5305 with the ATR inhibitor ceralasertib for the treatment of PARPi-resistant cancer - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/mct/article/22/12_Supplement/B058/730328/Abstract-B058-Combination-of-the-PARP1-selective
23. NCT04644068 | Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | ClinicalTrials.gov, accessed September 11, 2025, https://www.clinicaltrials.gov/study/NCT04644068
24. PETRANHA: Phase 1/2 study of AZD5305 + novel hormonal agents in patients with metastatic prostate cancer–Interim safety and pharmacokinetic results. - ASCO Publications, accessed September 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2024.42.4_suppl.123
25. Saruparib (AZD5305) vs Placebo in Men with Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - AstraZeneca Clinical Trials, accessed September 11, 2025, https://www.astrazenecaclinicaltrials.com/study/D9723C00001/
26. Study Details | NCT06120491 | Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | ClinicalTrials.gov, accessed September 11, 2025, https://www.clinicaltrials.gov/study/NCT06120491
27. Saruparib (AZD5305) plus Camizestrant compared with CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - EvoPAR-BR01 - AstraZeneca Clinical Trials, accessed September 11, 2025, https://www.astrazenecaclinicaltrials.com/study/D9722C00001/
28. Phase III, double-blind, placebo-controlled, 2-cohort, randomized study of saruparib (AZD5305) in combination with androgen receptor pathway inhibitors in patients with metastatic hormone-sensitive prostate cancer with and without homologous recombination repair mutation (EvoPAR-Prostate01). | Journal of Clinical Oncology - ASCO Publications, accessed September 11, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.TPS279
29. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/​6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/​ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer (EvoPAR-BR01) - Clinical Trials, accessed September 11, 2025, https://www.clinicaltrials.gov/study/NCT06380751
30. Abstract CT007: PETRA: First in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients (pts) with BRCA1/2, PALB2 or RAD51C/D mutations - Apollo, accessed September 11, 2025, https://www.repository.cam.ac.uk/items/8f500a38-c692-41e3-8ba8-39d37303c90d
31. Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA) : treatment, accessed September 11, 2025, https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra
32. Novel PARP inhibitor shows promise across solid tumors, including prostate cancer, accessed September 11, 2025, https://www.urologytimes.com/view/novel-parp-inhibitor-shows-promise-across-solid-tumors-including-prostate-cancer
33. AACR 2022: Next-generation PARP1-selective inhibitor demonstrates promising clinical activity with a favourable safety profile - ecancer, accessed September 11, 2025, https://ecancer.org/en/news/21761-aacr-2022-next-generation-parp1-selective-inhibitor-demonstrates-promising-clinical-activity-with-a-favourable-safety-profile
34. AZD5305 Yields Promising Clinical and Safety Findings Across Several Solid Malignancies, accessed September 11, 2025, https://www.cancernetwork.com/view/azd5305-yields-promising-clinical-and-safety-findings-across-several-solid-malignancies
35. Next-Gen PARP Inhibitor Effective in Breast Cancer - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/cdnews/news/1409/Next-Gen-PARP-Inhibitor-Effective-in-Breast-Cancer
36. Saruparib Shows Favorable Activity, Safety in Mutant Advanced Solid Tumors - CancerNetwork, accessed September 11, 2025, https://www.cancernetwork.com/view/saruparib-shows-favorable-activity-safety-in-mutant-advanced-solid-tumors
37. Full-year-and-Q4-2023-results-clinical-trials-appendix.pdf - AstraZeneca, accessed September 11, 2025, https://www.astrazeneca.com/content/dam/az/PDF/2023/fy/Full-year-and-Q4-2023-results-clinical-trials-appendix.pdf
38. AstraZeneca advances its pipeline and highlights progress in immuno-oncology, ADCs, cell therapy and epigenetics at AACR, accessed September 11, 2025, https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr.html
39. Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents - NCI, accessed September 11, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-00268
40. Abstract 4201: Combination of the PARP1-selective inhibitor saruparib with androgen receptor pathway inhibition provides combination benefit in preclinical models of prostate cancer with or without homologous recombination repair deficiency - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/cancerres/article/85/8_Supplement_1/4201/761010/Abstract-4201-Combination-of-the-PARP1-selective
41. EvoPAR-BR01: Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - AstraZeneca Breast Cancer Study Locator, accessed September 11, 2025, https://www.breastcancerstudylocator.com/trial/listing/479895
42. Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer - NCI, accessed September 11, 2025, https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2024-08484
43. Abstract P2-10-17: A randomized phase III study of first-line saruparib (AZD5305) + camizestrant vs CDK4/6i plus physician's choice endocrine therapy or + camizestrant in patients w/ BRCA1/BRCA2/PALB2 mutations & HR+/HER2- advanced breast cancer (EvoPAR-Breast01) | Clinical Cancer Research - AACR Journals, accessed September 11, 2025, https://aacrjournals.org/clincancerres/article/31/12_Supplement/P2-10-17/754044/Abstract-P2-10-17-A-randomized-phase-III-study-of
44. Cancer Accelerated Approvals - Withdrawn - FDA, accessed September 11, 2025, https://www.fda.gov/drugs/resources-information-approved-drugs/withdrawn-cancer-accelerated-approvals
45. Lynparza | European Medicines Agency (EMA), accessed September 11, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza
46. National registers of authorised medicines | European Medicines Agency (EMA), accessed September 11, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
47. New FDA and EMA Drug Approvals in Q2 2023 - Aptitude Health, accessed September 11, 2025, https://www.aptitudehealth.com/oncology-news/new-treatment-options-oncology-fda-ema-drug-approvals-q2-2023/
48. News | Clinical Oncology News & Insights | OncLive | Page 90, accessed September 11, 2025, https://www.onclive.com/news?p=159&page=90
49. Breakthrough Therapy - FDA, accessed September 11, 2025, https://www.fda.gov/patients/fast-track-breakthrough-therapy-accelerated-approval-priority-review/breakthrough-therapy
50. Ifinatamab Deruxtecan Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Pretreated Extensive-Stage Small Cell Lung Cancer - Daiichi Sankyo, Inc., accessed September 11, 2025, https://daiichisankyo.us/press-releases/-/article/ifinatamab-deruxtecan-granted-breakthrough-therapy-designation-by-us-fda-for-patients-with-pretreated-extensive-stage-small-cell-lung-cancer
51. Revolution Medicines Announces FDA Breakthrough Therapy Designation for Elironrasib, accessed September 11, 2025, https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-announces-fda-breakthrough-therapy-0/
52. FDA Grants Breakthrough Therapy Designation to Sacituzumab Tirumotecan (sac-TMT) for the Treatment of Certain Patients With Previously Treated Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer With EGFR Mutations - Merck.com, accessed September 11, 2025, https://www.merck.com/news/fda-grants-breakthrough-therapy-designation-to-sacituzumab-tirumotecan-sac-tmt-for-the-treatment-of-certain-patients-with-previously-treated-advanced-or-metastatic-nonsquamous-non-small-cell-lung-ca/
53. Breakthrough Therapy Designation - Friends of Cancer Research, accessed September 11, 2025, https://friendsofcancerresearch.org/breakthrough-therapies/
54. Breakthrough Therapy Approvals - FDA, accessed September 11, 2025, https://www.fda.gov/drugs/nda-and-bla-approvals/breakthrough-therapy-approvals
55. Current status and future promise of next-generation poly (ADP-Ribose) polymerase 1-selective inhibitor AZD5305 - PMC, accessed September 11, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9899804/